A collaborative U-M team shows that liver injury is less likely to originate from popular cancer immunotherapy drug, pembrolizumab, than tumor progression.

U-M researchers identify a potential treatment for non-alcoholic fatty liver disease.

A cutting-edge imaging strategy could significantly improve survival rates among patients at risk for liver cancer.

Hepatitis C rates have surged in the U.S. as drug use and opioid abuse have risen. A Michigan Medicine hepatologist reflects on the troubling trend.